rhEPO联合左卡尼汀对尿毒症肾性贫血患者高通量血液透析的效果

Effect of r RhEPO Combined with L-carnitine on High-flux Hemodialysis in Patients with Uremic Renal Anemia

目的 研究rhEPO联合左卡尼汀对尿毒症肾性贫血患者高通量血液透析的效果。方法 选取2019年6月-2021年6月在我院接受高通量血液透析的70例尿毒症肾性贫血患者,根据随机数字表达法将其分为研究组和对照组,对照组行rhEPO治疗,研究组行rhEPO联合左卡尼汀治疗,观察两组患者治疗前后贫血指标及血浆内皮素水平,心脏形态指标,不同时间点rhEPO用量。结果 治疗后,研究组血红蛋白等贫血指标分别为(103.23±6.02)g/L、(27.87±2.58)%、(35.23±3.62)g/L,改善情况显著优于对照组(P<0.05)。治疗后,研究组血浆内皮素水平为(134.67±6.54)pg/m L,显著低于对照组(P<0.05)。治疗后,研究组左心房内径等心脏形态指标分别为(32.06±0.12)mm、(32.72±0.36)mm、(56.6±0.59)mm改善情况显著优于对照组(P<0.05)。治疗1月、2月后研究组rhEPO用量为(4897.56±98.34)U,(3398.24±84.78)U显著低于对照组(P<0.05)。结论 尿毒症肾性贫血高通量血液透析患者行rhEPO联合左卡尼汀治疗可以有效改善患者贫血指标,改善心室重建,降低rhEPO用量。

Objective: To study the effect of rhEPO combined with L-carnitine on high-flux hemodialysis in patients with uremic renal anemia. Methods: 70 patients with uremic renal anemia who received high-flux hemodialysis in our hospital from June 2019 to June 2021 were selected, and divided into the study group and the control group according to the random number expression method. The control group received rhEPO therapy, and the study group received rhEPO combined with L-carnitine therapy. Anemia indexes, plasma endothelin levels, cardiac morphological indexes, and rhEPO dosage at different time points were observed in the two groups before and after treatment. Results: After treatment, the improvement of hemoglobin and other anemia indexes in the study group were(103.23±6.02) g/L,(27.87±2.58)%, and(35.23±3.62) g/L, respectively, which were significantly better than those in the control group(P<0.05). After treatment, the plasma endothelin level in the study group was(134.67±6.54) pg/m L, which was significantly lower than that in the control group(P<0.05). After treatment, the improvement of the left atrial diameter and other cardiac morphological indicators in the study group were(32.06±0.12) mm,(32.72±0.36) mm, and(56.69±0.59) mm, respectively, which were significantly better than those in the control group(P<0.05). After 1 month and 2 months of treatment, the dosage of rhEPO in the study group was(4897.56±98.34) U and(3398.24±84.78) U,which were significantly lower than those in the control group(P<0.05). Conclusion: High-flux hemodialysis patients with uremic renal anemia treated with rhEPO combined with L-carnitine can effectively improve the anemia indicators,improve ventricular remodeling, and reduce the dosage of rhEPO.